A New Way Forward
for Autoimmune Disease
CEO Fireside
Changing What’s Possible in Autoimmune Treatment
Nkarta CEO Paul Hastings, a lifelong patient advocate, breaks down natural killer cell therapy and how it could potentially transform the therapeutic landscape in autoimmunity.
Patients First
Our Clinical Trial Promise
Instead of asking people with serious diseases to reconstruct their lives around our studies, drug developers should be striving to design our research around their lives. Read about what we’re doing to make clinical trial opportunities more accessible and equitable.
Nature
Boosted Killer Cells Show Promise For Autoimmune Disease
“Supercharged ‘natural killer’ cells could become a potent way to reset a disordered immune system,” according to one of the world's most prestigious scientific journals.
Our Autoimmune Targets
We are dedicated to realizing the potential of natural killer (NK) cells for the treatment of autoimmune diseases. Our proprietary technology is designed to harness the inherent disease-fighting capabilities of these immune cells to act against cells that are dysfunctional, diseased or otherwise abnormal.
Follow us on Linkedin
Team Nkarta’s clinical leaders recently traveled to Houston for Kidney Week, the world’s largest annual nephrology conference, hosted by the American Society of Nephrology (ASN).
We focused on introducing a new therapeutic modality, CAR-NK, to nephrologists and discussed the scientific potential of cell therapy to benefit their patients.
Nkarta is in the clinic with an investigational cell therapy with the potential to advance future treatment options for patients living with lupus nephritis and primary membranous nephropathy. We came away from ASN with new opportunities for KOL partnerships, trial participation, and site expansion.
To learn more about our clinical trial in these indications, visit the Ntrust-1 website: https://www.ntrust1.com/
